Daniel de Boer, ProQR CEO (via YouTube)
February 11, 2022 10:40 AM ESTUpdated 11:35 AM
R&D

In lat­est an­ti­sense fail­ure, Pro­QR's rare eye dis­ease treat­ment falls flat

Jason Mast

Editor

It’s been a bad 12 months for an­ti­sense tech­nol­o­gy.

Pro­QR, an RNA-fo­cused start­up, an­nounced Fri­day that its lead can­di­date for one form of a rare …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times